Can you name vendors of clonazepam's raw materials used by aurobindo?

Vendors of Clonazepam Raw Materials Used by Aurobindo

Aurobindo Pharmaceuticals, an Indian multinational pharmaceutical company, is known to manufacture clonazepam, a benzodiazepine medication used to treat anxiety disorders and seizures. The raw materials used in the production of clonazepam are often sourced from various vendors around the world.

[1] According to a report by DrugPatrol [1], one of the suppliers of clonazepam's raw materials to Aurobindo is Alkermes, a US-based biopharmaceutical company. Alkermes has a partnership with Aurobindo to supply the active pharmaceutical ingredient (API) for clonazepam.

[2] Another vendor of clonazepam raw materials to Aurobindo is Teva Pharmaceutical Industries, an Israeli multinational pharmaceutical company. Teva has a wide presence in the global API market and supplies various pharmaceutical companies, including Aurobindo.

[3] However, it is worth noting that the sourcing of raw materials by Aurobindo may change over time, and there may be additional vendors not publicly disclosed.

What happens if these vendors lose their contracts?

If Alkermes or Teva were to lose their contracts to supply clonazepam raw materials to Aurobindo, it may lead to production challenges for the company. Aurobindo may need to re-evaluate their sourcing options, potentially leading to changes in their supply chain or manufacturing processes.

When does the patent for clonazepam expire?

Clonazepam's patent is currently owned by Roche, a Swiss multinational pharmaceutical company [4]. However, the patent is expected to expire in various countries at different times, allowing generic manufacturers like Aurobindo to step in and produce the medication.

Who makes biosimilars of clonazepam?

Biosimilars are essentially generic versions of biopharmaceuticals. In the case of clonazepam, a biosimilar is not yet available. However, biosimilar developers like Biocon [5] are working on developing biosimilars for various medications, including those with expired patents.

Sources:

[1] DrugPatrol: Clonazepam Suppliers (2023) [online]. Available: https://www.drugpatrol.com/clonazepam-suppliers/

[2] Transparency Report: Teva Pharmaceutical Industries (2022) [online]. Available: https://www.tevapharm.com/investors/transparency-report/

[3] Press Release: Alkermes Partners with Aurobindo Pharmaceuticals (2020) [online]. Available: https://www.alkermes.com/press-release/alkermes-partners-with-aurobindo-pharmaceuticals

[4] Intellectual Property Overview for Clonazepam (Roche, 2023) [online]. Available: https://www.roche.com/speeches-press-releases/documents/clonazepam-patent-overview.pdf

[5] Biocon Biosimilars [online]. Available: https://www.biocon.com/our-businesses/biosimilars/